American Journal of Cardiology
Volume 103, Issue 8 , Pages 1056-1060 , 15 April 2009

Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)

  • Patricia Tung, MD, MPP

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • Stephen D. Wiviott, MD

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-278-0145; fax: 617-975-0955
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • Sabina A. Murphy, MPH

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • Carolyn H. McCabe, BS

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • C. Michael Gibson, MD, MS

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Department of Medicine, Harvard Medical School, Boston, Massachusetts

Received 27 August 2008 ,Revised 9 December 2008 ,Accepted 9 December 2008.

References 

  1. Rastam L, Hannan PJ, Luepker RV, Mittelmark MB, Murray DM, Slater JS. Seasonal variation in plasma cholesterol distributions: implications for screening and referral. Am J Prev Med. 1992;8:360–366
  2. Woodhouse PR, Khaw KT, Plummer M. Seasonal variation of serum lipids in an elderly population. Age Ageing. 1993;22:273–278
  3. Gordon DJ, Trost DC, Hyde J. Seasonal cholesterol cycles: the Lipid Research Clinics Coronary Primary Prevention Trial placebo group. Circulation. 1987;76:1224–1231
  4. Cheng T. Mechanism of seasonal variation in acute myocardial infarction. Int J Cardiol. 2005;100:163–164
  5. Manttari M, Javela K, Koskinen P. Seasonal variation in high density lipoprotein cholesterol. Atherosclerosis. 1993;100:257–265
  6. Mustad V, Derr J, Reddy CC, Pearson TA, Kris-Etherton PM. Seasonal variation in parameters related to coronary heart disease risk in young men. Atherosclerosis. 1996;126:117–129
  7. Gordon DJ, Hyde J, Trost DC. Cyclic seasonal variation in plasma lipid and lipoprotein levels: the Lipid Research Clinics Coronary Primary Prevention Trial Placebo Group. J Clin Epidemiol. 1988;41:679–689
  8. Rippey R. Overview: seasonal variations in cholesterol. Prev Med. 1981;10:655–659
  9. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002;89:860–861
  10. Cannon CP, Braunwald E, McCabe CH. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  11. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  12. Buxtorf JC, Baudet MF, Martin C, Richard JL, Jacotot B. Seasonal variations of serum lipids and apoproteins. Ann Nutr Metab. 1988;32:68–74
  13. Baigent C, Keech A, Kearney PM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278

 The PROVE IT-TIMI 22 Study was supported by a research grant from Bristol-Myers Squibb, New York, New York. Dr. Wiviott has received honoraria for speaking from Pfizer, New York, New York, and Merck and Co., Whitehouse Station, New Jersey, and consulting fees from Sanofi-Aventis, Bridgewater, New Jersey. Dr. Cannon currently receives research grants/support from Accumetrics, San Diego, California, AstraZeneca, Wilmington, Delaware, Bristol-Myers Squibb/Sanofi Partnership, New York, New York, Glaxo Smith Kline Brentford, Middlesex, United Kingdom, and Merck/Schering Plough Partnership, Kenilworth, New Jersey.

PII: S0002-9149(09)00042-3

doi: 10.1016/j.amjcard.2008.12.034

American Journal of Cardiology
Volume 103, Issue 8 , Pages 1056-1060 , 15 April 2009

Article Tools

* Image Usage & Resolution